Q-omics provides the consensus-scored MIR107 profile across patient tissues and cancer cell-line models. MIR107 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MIR107 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, MIR107 RNA expression shows 5,949 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, THCA, and STAD as cancer lineages where MIR107 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR107 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR107 survival associations across molecular data types. MIR107 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR107 RNA expression–survival associations across cancer types. High MIR107 expression shows unfavorable associations in CHOL, LIHC, COAD, THYM, LUAD and KICH. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MIR107 RNA expression.
This table summarizes MIR107 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR107. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR107 shows lower tumor expression in THCA and higher tumor expression in PRAD. The THCA box plot shows higher MIR107 RNA expression in normal versus tumor tissue (log2 FC = −0.243, t-test p = .001).
This table shows molecular features associated with MIR107 in patient tissues and cancer cell lines. In patient samples, MIR107 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
